160 Federal Register / Vol. 76, No. 1 / Monday, January 3, 2011 / Notices 

the U.S., and is unfortunately overrepresented in minority, immigrant, and 

low socio-economic populations. The 

proper detection and treatment of lead 

poisoning relies entirely on the accurate 

and precise measurement of blood lead 

concentration. EP is utilized as an 

adjunct test to indicate the extent and 

duration of lead exposure, as well as the 

detection of iron deficiency, another 

pediatric health issue. Proficiency 

testing (PT) is a proven method for 

assuring and improving laboratory test 

accuracy. This program has costeffectively provided monthly PT and 

other lab quality improvement tools to 

nearly 600 laboratories across the U.S. 

and beyond. Of note, the primary focus 

of the program over the last few years 

has been the integration of new and 

usually inexperienced participants into 

the program. An enrollment boom has 

been fueled by proliferation of the CLIAwaived LeadCare II point of care testing 

instrument. In the three years since its 

introduction, LeadCare II enrollment 

has grown from zero to 300 laboratories, 

comprising approximately 40 percent of 

all participants. Continued participation 

increases, and the fact that those 

increases are nearly totally comprised of 

LeadCare II users, represent both a 

public health success and a challenge 

for this program. Since its introduction 

in early 2007, over 300 of these 

laboratories have enrolled for PT, 

swelling program participation to 800 

laboratories. 

SUPPLEMENTARY INFORMATION: 

Intended Recipients of the Award: 

University of Wisconsin, Laboratory of 

Hygiene, Madison, Wisconsin. 

Amount of the Non-Competitive 

Supplemental Funding: $250,000. 

Authority: Section 501(c)(1) of the Social 

Security Act, as amended. 

CFDA Number: 93.110. 

Proposed Project Period: January 1, 

2008–October 31, 2011. 

Justification for Exception to 

Competition: 

The participation of large numbers of 

these labs in voluntary proficiency was 

by design, and represents a public 

health success by assuring blood lead 

screening accuracy where there would 

otherwise be no evaluation. Three 

factors contribute to this. First, is the 

HRSA support of this program, which 

has been increased to accommodate the 

additional labs. 

This support allows laboratories to 

participate at no cost, a vital 

consideration for voluntary participants. 

The second factor is the effort of the 

NBLPT Program to integrate the new 

technology shortly after it became 

available, and collaboration with the 

manufacturer to promote participation. 

The third factor is that some States have 

initiated PT requirements, deeming this 

quality check of sufficient importance to 

mandate successful participation as a 

requisite for Medicaid reimbursement. 

This State-level action illustrates the 

importance of this PT participation, and 

may be the beginning of a trend that will 

serve to increase participation even 

more. 

The University of Wisconsin will use 

these funds to initiate an orderly 

closeout of HRSA-funded activities 

which clearly falls within the purview 

of the Centers for Disease Control and 

Prevention’s ‘‘Preventing Lead Poisoning 

in Young Children’’ initiative at their 

National Center for Environmental 

Health. This extension with funding 

will also accord the University of 

Wisconsin and the Center to solicit 

recommendations from the CDC’s 

Advisory Committee on Childhood Lead 

Poisoning Prevention with respect to 

future funding for this activity. 

FOR FURTHER INFORMATION CONTACT: 

David Heppel, M.D., Director, Division 

of Child, Adolescent and Family Health, 

Maternal and Child Health Bureau, 

Health Resources and Services 

Administration, 5600 Fishers Lane, 

Room 18A–30, Rockville, MD 20857; 

301–443–2250; dheppel@hrsa.gov. 

Dated: December 23, 2010. 

Mary K. Wakefield, 

Administrator. 

[FR Doc. 2010–33063 Filed 12–30–10; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

National Advisory Committee on Rural 

Health and Human Services; Notice of 

Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), announcement is 

made of the following National 

Advisory body scheduled to meet 

during the month of February 2011. 

The National Advisory committee on 

Rural Health will convene its sixtyseventh meeting in the time and place 

specified below: 

Name: National Advisory Committee 

on Rural Health and Human Services. 

Dates and Times: 

February 23, 2011, 8:45 a.m.–5 p.m. 

February 24, 2011, 8:45 a.m.–4 p.m. 

February 25, 2011, 8:45 a.m.–11:15 a.m. 

Place: Omni Shoreham Hotel, 2500 

Calvert Street, NW., Washington, DC 

20008. 

Phone: (202) 234–0700. 

Status: The meeting will be open to 

the public. 

Purpose: The National Advisory 

Committee on Rural Health and Human 

Services provides advice and 

recommendations to the Secretary with 

respect to the delivery, research, 

development and administration of 

health and human services in rural 

areas. 

Agenda: Wednesday morning at 9 

a.m. the meeting will be called to order 

by the Chairperson of the Committee, 

the Honorable Ronnie Musgrove. There 

will be an update from officials from the 

Department of Health and Human 

Services. This will be followed by a 

series of panel presentations on key 

provisions from the Affordable Care Act 

(ACA). The Committee will be 

examining the rural implications of 

several provisions from the ACA, 

including health insurance exchanges, 

the Maternal and Early Childhood Home 

Visitation program and the Community 

Living Assistance, Services and Support 

program. The day will conclude with a 

period of public comment at 

approximately 4:30 p.m. 

Thursday morning at 9 a.m. the 

Committee will continue to hear panel 

presentations on ACA-related 

provisions and will then break into 

subcommittees on each of those topics 

for further discussion. The day will 

conclude with a period of public 

comment at approximately 4:30 p.m. 

Friday morning at 9 a.m. the 

Committee will summarize key findings 

from the meeting and develop a work 

plan for the next quarter and the June 

meeting. 

FOR FURTHER INFORMATION CONTACT: 

Thomas Morris, MPA, Executive 

Secretary, National Advisory Committee 

on Rural Health and Human Services, 

Health Resources and Services 

Administration, Parklawn Building, 

Room 10B–45, 5600 Fishers Lane, 

Rockville, MD 20857, Telephone (301) 

443–0835, Fax (301) 443–2803. 

Persons interested in attending any 

portion of the meeting should contact 

Tish Scolnick at the Office of Rural 

Health Policy (ORHP) via Telephone at 

(301) 443–0835, or by e-mail at 

nscolnick@hrsa.gov. The Committee 

meeting agenda will be posted on 

ORHP’s Web site http:// 

www.ruralhealth.hrsa.gov. 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 76, No. 1 / Monday, January 3, 2011 / Notices 161 

Dated: December 27, 2010,, 

Robert Hendricks, 

Director, Division of Policy and Information 

Coordination. 

[FR Doc. 2010–33062 Filed 12–30–10; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The concept meeting, 

proposals and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the contract proposals, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel. Contraceptive 

Clinical Trials Network. 

Date: January 12, 2011. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate concept 

review. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Room 2A01, Rockville, 

MD 20852. (Telephone Conference Call). 

Contact Person: Sathasiva B. Kandasamy, 

PhD, Scientific Review Administrator, 

Division of Scientific Review, National 

Institute of Child Health and Human 

Development, 6100 Executive Boulevard, 

Rockville, Md 20892–9304. (301) 435–6680. 

skandasa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment program, National 

Institutes of Health, HHS) 

Dated: December 27, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–33067 Filed 12–30–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel. 

Date: January 10, 2011. 

Time: 12:45 p.m. to 3 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Room 2A01, Rockville, 

MD 20852. (Telephone Conference). 

Contact Person: Sathasiva B. Kandasamy, 

PhD, Scientific Review Administrator, 

Division of Scientific Review, National 

Institute of Child Health and Human 

Development, 6100 Executive Boulevard, 

Rockville, MD 20892–9304. (301) 435–6680. 

skandasa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: December 27, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–33068 Filed 12–30–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories and 

Instrumented Initial Testing Facilities 

Which Meet Minimum Standards To 

Engage in Urine Drug Testing for 

Federal Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908); 

September 30, 1997 (62 FR 51118); 

April 13, 2004 (69 FR 19644); November 

25, 2008 (73 FR 71858); December 10, 

2008 (73 FR 75122); and on April 30, 

2010 (75 FR 22809). 

A notice listing all currently certified 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) is published in 

the Federal Register during the first 

week of each month. If any Laboratory/ 

IITF’s certification is suspended or 

revoked, the Laboratory/IITF will be 

omitted from subsequent lists until such 

time as it is restored to full certification 

under the Mandatory Guidelines. 

If any Laboratory/IITF has withdrawn 

from the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http:// 

www.workplace.samhsa.gov and http:// 

www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 2– 

1042, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were initially 

developed in accordance with Executive 

Order 12564 and section 503 of Public 

Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs’’, as amended in the 

revisions listed above, requires {or set} 

strict standards that Laboratories and 


jlentini on DSKJ8SOYB1PROD with NOTICES